Annual Meeting 2016 : Next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies

Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses the next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies at ASCO GI 2016